• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

kyliem@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
Education
PhD
University of Melbourne
Bachelors Degree
University of Melbourne
ORCID

0000-0002-6238-4092

A/Prof Kylie Mason

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

57 Scholarly works
1 Projects

HIGHLIGHTS

  • 2025

    Journal article

    Position statement on the management of pregnancy in sickle cell disease
    DOI: 10.1111/ajo.13888
  • 2025

    Journal article

    Management of hairy cell leukaemia in pregnancy
    DOI: 10.1177/1753495X251356377
  • 2013

    Journal article

    ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
    DOI: 10.1038/nm.3048
  • 2011

    Journal article

    Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
    DOI: 10.1182/blood-2011-04-347849
  • 2009

    Journal article

    Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function
    DOI: 10.1182/blood-2009-01-200345
  • 2009

    Journal article

    The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia
    DOI: 10.1038/leu.2009.151
  • 2008

    Journal article

    In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
    DOI: 10.1073/pnas.0809957105
Kylie Mason

Latest Honours,
Awards and Fellowships


2004
Fellow of the Royal Australasian College of Physicians (FRACP)
2004
Fellow of the Royal College of Pathologists, Australia (FRCPA)

RECENT SCHOLARLY WORKS

  • 2024

    Journal article

    Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry
    DOI: 10.1111/imj.16297
  • 2024

    Journal article

    Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study
    DOI: 10.1093/neuonc/noad224
  • 2024

    Journal article

    Experiences of cohabiting partners of women diagnosed with cancer during pregnancy: a qualitative study
    DOI: 10.1007/s00520-024-08570-8
  • 2024

    Journal article

    Thrombosis in patients with immune thrombocytopenia: incidence, risk, and clinical outcomes
    DOI: 10.1016/j.rpth.2024.102342
  • 2024

    Journal article

    Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials
    DOI: 10.1136/bmjopen-2023-076246
  • 2023

    Journal article

    Favourable outcomes with an initial active surveillance strategy for asymptomatic radiation-induced meningiomas in long-term survivors of paediatric and young adult malignancies
    DOI: 10.1016/j.radonc.2023.109916
  • 2023

    Journal article

    The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance
    DOI: 10.1111/bjh.18727
  • 2023

    Journal article

    Proinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels
    DOI: 10.1182/bloodadvances.2022007849

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224